Background: Medication adherence may be a proxy for healthy behaviors and other factors that affect outcomes. Prior studies of the association between placebo adherence and health outcomes have been limited primarily to men enrolled in clinical trials and cardiovascular disease outcomes. We examined associations between adherence to placebo and the risk of fracture, coronary heart disease, cancer, and all-cause mortality in the 2 Women's Health Initiative hormone therapy randomized trials.
M edication adherence is an important topic within the medical community, with numerous studies demonstrating suboptimal adherence with a wide variety of drugs, including oral osteoporosis medications and therapies for hyperlipidemia and hypertension. [1] [2] [3] [4] [5] [6] [7] Between 25% and 50% of new users of these medications discontinue within 1 year of initiation. The potential importance of this finding is underscored by observational studies demonstrating significant differences in the risk for fracture, cardiovascular events, and mortality comparing adherent and nonadherent persons. [8] [9] [10] [11] [12] However, a largely unexplored potential source of confounding related to medication adherence is the possibility that other healthy behaviors are also present in persons adherent to medications. This might lead to beneficial effects independent of the medication effect, which has been called a "healthy adherer" effect. In fact, randomized, placebocontrolled trials (RCTs) evaluating drug therapy, mainly after myocardial infarction (MI) in men, have demonstrated lower mortality risk in patients with higher placebo adherence, [13] [14] [15] lending credence to the possibility that good adherence itself is associated with a lower risk of adverse outcomes. The healthy adherer effect is hypothesized to be a surrogate for other healthy behaviors, 16, 17 which may or may not be able to be measured and controlled for in analyses of observational data or trials. It is not clear whether the healthy adherer effect extends to clinical outcomes other than MI, to healthy populations, or to women.
To examine these issues, we used data from the placebo arms of the 2 hormone therapy (HT) RCTs of the Women's Health Initiative (WHI), which enrolled relatively healthy postmenopausal women. We studied the relationship between placebo adherence and the risk for fracture, coronary heart disease (CHD), malignancy, cause-specific mortality, and all-cause mortality. We also examined the extent to which the healthy adherer effect is carried over to other medication-taking behavior for hyperlipidemia and osteoporosis. We selected these conditions because they are chronic and asymptomatic; thus, good adherence is more likely because of a healthy adherer effect and less likely to be attributable to symptom-relieving behavior.
METHODS

Cohort and Patient Eligibility Criteria
All women participating in the 2 HT trials of the WHI who were randomized to placebo were eligible for analysis. More complete descriptions of the HT trials, [18] [19] [20] patient recruitment and study implementation have been previously published. 21, 22 A 3-month wash-out period was required for women presenting with current HT use. The WHI trial evaluating estrogen plus progestin randomized 16,608 postmenopausal women with no prior hysterectomy to active HT or placebo. The separate WHI trial evaluating estrogen alone randomized 10,739 postmenopausal women with prior hysterectomy to active HT or placebo. Differences in the characteristics of participants in these 2 trials have been previously described. 19 Women were not eligible for this analysis if they experienced an outcome of interest or withdrew from the HT study before the first measurement of adherence.
All study pills, hormones, or identical-appearing placebo were dispensed at the WHI clinical centers using a computerized dispensing system, blinding both participants and clinical staff to randomization allocation. For breast cancer safety, all participants were required to have annual clinical breast exams (performed at the clinical centers) and annual screening mammography.
Characterization of Adherence
For this analysis, and consistent with recommendations from the International Society of Pharmacoeconomics and Outcomes Research, adherence was used as a general term and was defined by the extent to which a patient's behavior coincides with the prescribed treatment regimen. 23 It can be quantified as persistence, which captures the length of time a patient continues with therapy, or as compliance, typically quantified as a medication possession ratio (MPR) or as the proportion of days covered (PDC). The MPR and the PDC are equivalent if the MPR is capped at a maximum of 100%.
For this analysis, we quantified adherence as the PDC, calculated as the number of days for which the study medication was dispensed (based on dispensing history) minus the number of days of untaken pills (based on remaining study pills returned) divided by the number of days between visits. While enrolled in the study, women had an annual clinic visit and a semiannual contact by phone, mail, or in-person clinic visit. At each clinic visit, women were asked to return all their study medication bottles. To assess PDC, pill counts in the returned medication bottles were evaluated. Between 1993 and 1996, a pill counter was used; subsequently, pill weighing was used to estimate remaining pill number. This process was not observed by or discussed with participants. However, a PDC below 80% initiated efforts of future staff to increase adherence for both the placebo and intervention arms, and study personnel remained blinded to treatment arm. The mean interval between study visits at which adherence was assessed was approximately 6 months; 95% of intervals over which adherence was assessed were 1 year or less.
Although selection of an adherence threshold is arbitrary, we initially categorized PDC as r50%, >50 and <80%, and Z80%, after prior conventions. 8, 24 Because some outcome models were unstable, with <10 events in at least 1 of the lower 2 categories of adherence, PDC was subsequently collapsed to 2 categories of <80% versus Z80%. The main exposure variable of interest was cumulative (ie, average) PDC since the beginning of observation. Because there were multiple adherence assessments available per participant, PDC varied over time in the analysis. As part of a sensitivity analysis, we examined outcomes in relation to adherence only for the most recent time interval; as results were minimally different compared with the main analysis, these data are not presented.
Outcome Assessment
Outcomes of interest were hip, clinical vertebral, and distal forearm (ie, wrist) fracture, CHD (MI or CHD death), invasive breast cancer, colorectal cancer, all invasive cancer, cancer death, and all-cause mortality. Case definitions for these outcomes were as defined in the WHI protocol. Selfreports of clinical outcomes were verified by medical record, and pathology report were reviewed by trained physician adjudicators. Outcomes were then centrally reviewed by physicians based on medical record review, [25] [26] [27] with blinding to randomization allocation.
Statistical Analysis
Descriptive statistics compared demographics, comorbidities, medication use, and other risk factors across adherence categories. Proportional hazards models modeled the time-varying relationship between adherence to placebo and outcomes of interest. 28 Adherence before fracture has been shown to differ from adherence after the fracture in a previous report, 8 and so adherence was measured for all participants before the events. Observation time began at the time of the first measurement of adherence and continued until a participant died or became lost to follow-up. In cases where a participant did not bring her pills in a particular visit, the adherence value from the previous visit was carried forward until her next known adherence value. Age and body mass index were modeled continuously; all other covariates were modeled categorically (categories shown as in Table 1 ). Covariates measured at baseline were selected on the basis of a priori interest and their inclusion in previous WHI reports examining the same outcomes; covariates used in the analysis are reported in the footnote of Table 2 .
We further examined the correlation between placebo adherence and adherence to hyperlipidemia and osteoporosis medications in the subset of clinical trial participants taking medications for these conditions (N = 883 and n = 158, respectively). In the WHI, use of nonstudy medications was not captured with sufficient detail that allowed for calculation of their PDC. Therefore, adherence with hyperlipidemia and osteoporosis medications was quantified as 1-year persistence, which was determined by self-report and medication bottle review at baseline and 1 year later. We defined high persistence with statins and osteoporosis pharmacotherapy as individuals remaining on therapy at 1 year.
Application of External Adjustment Methods to Control for the Healthy Adherer Effect in an Observational Analysis
Women who were high placebo adherers might be more likely to adhere to osteoporosis and lipid medications, suggesting that the behaviors and factors associated with healthy adherer effect may be in part independent of the medication itself, and thus generalizable across medication classes. For this reason, we considered higher adherence with osteoporosis and lipid medications as a proxy for unmeasured confounders related to the healthy adherer effect. An unmeasured confounder can be controlled for using external adjustment methods 29 by using information obtained from other studies where that confounder was measured to estimate (1) the differential prevalence of the confounder between groups and (2) the association between the confounder and the outcome. We demonstrated how one might use our results (from the placebo group) to adjust for the healthy adherer effect in an observational analysis of adherence to an active medication (eg, HT) where there is no placebo group in which adherence behavior can be directly measured. In this example, we use the result from the placebo adherence association with hip fractures, and the differential prevalence to osteoporosis and lipid medications between women adherent and nonadherent to placebo, to more fully adjust the effect of adherence to HT on fractures.
Using identical methods to those described previously for women randomized to placebo, we studied women in the HT arm of the WHI trial to estimate the relationship between adherence to HT and hip fracture. We compared women highly adherent (Z80%) to those less adherent (<80%) to HT, adjusting for the same confounders as for our placeboadherence models ( Table 2) . External adjustment techniques, 29 with the confounder of interest being nonadherence behavior, were used to yield a healthy adherer-adjusted HThip fracture result. In other words, the "missing" confounder that we controlled using external adjustment represented whatever factor(s) for which placebo adherence served as a proxy. This healthy adherer adjusted result was compared with the previously-reported result for the association between HT and hip fracture. 18, 20, 30 
RESULTS
Descriptive characteristics of the 13,444 WHI HT trial participants receiving placebo are in Table 1 . Older women, those better educated, and with higher household incomes were more adherent with the placebo regimen. Adherent women were less likely to smoke and consume low amounts of fruits and vegetables and had better self-reported health. Adherent women were more likely to have had Papanicolaou smears and colonoscopies and to have seen a healthcare provider in the previous year. In general, differences between groups defined by adherence were modest. Some statistically significant differences were of small magnitude and of little clinical significance.
The pattern of adherence over the course of the study is shown in Figure 1 . On average, a majority of women were highly adherent to study medication, although adherence decreased over time. Five years into the trial, about 25% of women were <80% adherent. Women reporting baseline moderate to severe climacteric symptoms had similar adherence to placebo as others (data not shown).
The main results of the study are shown in Table 2 . Adherence to placebo was significantly and inversely associated with all-cause mortality, hip fracture, MI, invasive breast cancer, and cancer-related death. Nonsignificant trends suggested a reduced incidence of all other outcomes except for wrist fracture and colon cancer. The crude and adjusted hazard ratios (HRs) were minimally different for most outcomes. In analyses for which we did have adequate numbers of outcome events to examine 3 categories of adherence (0% to 50%, >50% to <80%, Z80%), results for intermediate adherence (PDC, 50% to 80%) were in between those for high PDC and low PDC. Table 3 shows the association between adherence to placebo and persistence with statins and osteoporosis medications. Women highly adherent to placebo dispensed through the clinical trial had a 20% greater absolute difference in persistence with medications for hyperlipidemia and osteoporosis (prescribed for clinical indications) compared with women not highly adherent to placebo.
We could not directly adjust the HT-hip fracture result with the information on adherence to other medications, given that only a small proportion of women were taking these other medications. However, to demonstrate how one might adjust for the healthy adherer effect in the analysis of the effect of HT on hip fracture, we used external adjustment methods. The crude HR for the association between high adherence to HT and hip fracture was 0.43 [95% confidence interval (CI), 0.28-0.66]. After controlling for factors described in the footnote of Table 2 , the adjusted HR associated with high versus low HT adherence was 0.54 (95% CI, 0.34-0.84). On the basis of observed prevalence of low adherence to osteoporosis medication of 50% and 30% among women with low and high placebo adherence, results in Table 4 yielded a more fully-adjusted HR of 0.62. This change in the HR from 0.54 to (continued ) 0.62 is consistent with the external adjustment procedure providing some additional control for confounding related to the healthy adherer effect. Similar results were observed applying the differential prevalence of low adherence to statins.
DISCUSSION
Among postmenopausal women randomized to placebo in the 2 randomized HT trials of the WHI, we found a strong and significant inverse association between adherence to placebo and hip fracture, CHD, invasive breast cancer, cancer death, and all-cause mortality. The magnitude of this effect was greatest for hip fracture. On the basis of these results, the healthy adherer effect may be an important factor that could confound observational analyses, leading to overestimation of medication benefits. Analyzing a clinical trial only among the subgroup of adherent patients, rather than by intent-to-treat, may likewise be biased. All P values are from w 2 tests using a significance criterion of 0.05. Column % may not sum exactly to 100% due to rounding or to missing data. *Adherence was assessed as a fixed covariate for the purposes of descriptively comparing women; all other analyses evaluated adherence as time varying. CES-D indicates Center for Epidemiologic Studies Depression Scale; CVD, cardiovascular disease; GI, gastrointestinal; HF, hot flashes; HT, hormone therapy; MET, metabolic equivalent of task; NS, night sweats; NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor.
The association between placebo adherence in RCT and mortality risk has been examined in at least 8 previous reports. As summarized in a recent meta-analyses, high adherence to placebo was associated with lower all-cause mortality (HR, 0.45; 95% CI, 0.38-0.54). 12 Although the 8 trials included enrolled 1167 participants with 636 deaths, only 240 women were included, among whom 19 deaths occurred. In one of these trials, adherence was measured by self report only, and adherence in a second was based on clinician's impression. Objective measurement of adherence may differ from selfreports or subjective assessments. 31 Even despite some methodological heterogeneity in how adherence was as-sessed, these prior reports support an association with placebo adherence and lower mortality in men participating in drug therapy trials after MI. Only limited evidence is available regarding placebo adherence in healthier populations and on other clinical outcomes including mortality. Among the few studies conducted in women and consistent with our findings, an analysis of adherence to placebo in postmenopausal women participating in an osteoporosis clinical trial suggested a lower rate of hip fracture associated with placebo adherence, but there were few hip fracture events, and results were not statistically significant. 32 Our study was not designed to elucidate behaviors and other risk factor for which medication adherence may be a proxy, but factors associated with adherence to calcium and Vitamin D in the WHI has been described. 33 However, factors related to adherence with these supplements may differ compared with adherence with prescription medications like HT. Nevertheless, we can offer some observations about behaviors that did not account for the healthy adherer effect we observed. The healthy adherer adjusted results were minimally different than the unadjusted results for most outcomes, suggesting that none of the baseline factors we controlled for accounted for the healthy adherer effect; these included age, race, income, education, marital status, occupation, health insurance, health care seeking behavior, preventive services utilization, health behaviors like smoking and alcohol, exercise, diet, medical conditions and medications, and depression.
Although it is possible that the healthy adherer effect may be a proxy for unmeasured behaviors and health habits that WHI did not collect or that varied substantially over *Adjusted for age, ethnicity, education, smoking, alcohol, fruit/vegetables intake, red meat intake, BMI, physical activity, physical function, any insurance, mammogram, visit to usual care provider in the past year, colonoscopy ever, family history of fracture, family history of breast cancer, self-reported health, history of diabetes, bilateral oophorectomy, age at first birth, age at menarche, depression, aspirin, corticosteroids, fracture medication, beta blockers, thiazides, loop diuretics, PPIs, NSAIDs, lifetime hormone therapy duration, number of medications taken.
Ann % indicates Annualized %; BMI, body mass index; CHD, coronary heath disease; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor; WHI, Women's Health Initiative. time, these effects may not affect all outcomes. For example, despite the strong association seen with placebo adherence and hip fracture, there was no similar inverse relation between adherence and wrist fractures or colon cancer. Wrist fractures have a weaker association with osteoporosis than hip and vertebral fractures 34 and different risk factors 35 ; wrist fractures typically occur in healthier, more active women. It is also possible that the differential association between adherence and hip versus wrist fracture may be related to major changes in health state (ie, a "sick stopper" effect), whereby declining health, worsening comorbidities, and an associated competing focus on other health issues results in patients changing patterns of medication use, perhaps becoming less adherent. 36 These changes in health status may be more strongly associated with certain outcomes (eg, hip fracture) than others (eg, wrist fracture). The importance and magnitude of the healthy adherer effect also may vary by patient population. For example, an observational study of patients registered in a large database of post-MI patients in Ontario did not find evidence that outcome benefits were mediated by "healthy adherer" behavioral attributes. 37 Additional examination of time-varying confounders may be fruitful to better understand the pathway by which medication adherence as a behavior mediates its protective effect. We were unable to pursue this possibility because repeated measures of baseline factors were not made very frequently (ie, every 1 to 3 y). Future studies that can link clinical trials or observational registries to administrative claims data, where data capture is essentially continuous, may yield a better understanding of the healthy adherer effect. Such a linkage with administrative data could allow better understanding of major and rapid changes in health state (eg, new comorbidities, recent hospitalizations) and minimize loss to follow-up, although administrative data may be somewhat limited in providing clinically rich information.
Despite our lack of understanding of the pathway by which the "healthy adherer" effect operates, it may nevertheless be possible to at least partially control for its effect using external adjustment. 38, 39 In our study, the unmeasured confounder was adherence behavior. This information was used to adjust the association between high adherence to HT and hip fracture (HR, 0.54) to yield a healthy adhereradjusted HR of 0.62. Depending on the "true" value of the association of placebo adherence and hip fracture risk, the externally-adjusted HT-hip fracture HR may have ranged from 0.57 to as high as 0.68. Compared with our initially adjusted results, this result was closer to the result from the WHI HT RCT, which in the estrogen arm was 0.61 (0.41-0.91) 30 and in the estrogen+progestin arm was 0.67 (95% CI, 0.47-0.96). 18, 20 Without the adjustment for the healthy adherer effect, the benefit of HT was overestimated. External adjustment may provide an approach to control for the healthy adherer effect, independent of drug effect, and should be further examined in future studies. Of potential importance, adherence to hyperlipidemia and osteoporosis medications in WHI was self-reported, and some of the Table 3) . P l = 0.50 (prevalence of poor adherence behavior among women with low adherence to placebo, ie, prevalence of low/missing persistence with osteoporosis medications from Table 3 ).
RR placebo = 0.50 (95% CI = 0.33-0.78), inverted observed adjusted association between poor adherence to placebo and hip fracture, observed in Table 2 .
RR full = fully adjusted association between HT and hip fracture, after controlling for residual confounding (adherence behavior identified by adherence to osteoporosis pharmacotherapy).
Applying differential adherence to statins identifies similar externally-adjusted results, that is, RR = 0.63, with point estimates for the RR ranging from 0.57 to 0.69 depending on the true value of RR placebo .
*Example calculation per (28) ,
adherence data for these medications was missing (up to 15% of women). We categorized these missing data as nonpersistence, given that the occurrence of missing data was strongly associated with nonadherence to placebo study medication. Moreover, our estimates of adherence to hyperlipidemia and osteoporosis medications were from women taking these at baseline, many of whom were likely to have been longstanding, prevalent users. A more robust measure of association of adherence to these medications, studying new users and deriving more precise information from a data source such as a pharmacy claims database, might allow for better estimation of adherence behavior and thus permit more complete adjustment. Study strengths include a large, ethnically diverse study population of well-characterized postmenopausal women at a wide range of ages from 40 US centers. Adherence to trial medication or placebo was rigorously determined using a prospectively defined procedure and not based on self-report. Clinical outcomes were rigorously ascertained. Even for women who withdrew from the WHI, follow-up on the mortality end point was available in 98% of participants. Additionally, we were able to adjust for a broad and comprehensive set of healthy behaviors that have been postulated to explain at least some of the "healthy adherer" effect, although many of these factors were measured only at baseline. Despite these strengths, our study has some potential limitations. Small number of events for some outcomes (eg, colorectal cancer) required collapsing adherence categories into 2 levels, a convention we followed for all outcome analyses for consistency. Women were censored at the time they did not return for any further WHI study visits. If one assumes that these women were nonadherent, then it is likely that our results are conservative compared with the estimates we would obtain if we imputed nonadherence for these women and allowed them to remain in the analysis. Additionally, and despite the diverse nature of the more than 13,000 WHI clinical trial participants represented in our analysis, our findings may have limited generalizability to nontrial settings, although this would not compromise the internal validity of our results. Finally, adherence to a medication provided by a study like WHI may be different, and may be associated with different outcomes, than adherence to a medication prescribed for any other reason, although the direction of any potential bias is difficult to predict.
In conclusion, we report that adherence to placebo was associated with improved clinical outcomes and lower allcause mortality, suggesting that the healthy adherer effect is important across a broader set of outcomes than previously reported, and is relevant for community-dwelling women as well as men. This work underscores the importance of developing, as part of a future research agenda, a better understanding of the healthy adherer effect, both in terms of the behaviors or factors that mediate the observed beneficial effects, and as well as how adherence changes over time in relation to changes in health states. In the meantime, we have presented one approach to adjust for this healthy adherer effect to provide more valid estimates of benefits due to the medication rather than factors solely associated with adherence itself.
